Summary

The Asia Pacific botulinum toxin market was valued at US$ 925.29 million in 2023 and is expected to reach US$ 2,743.18 million by 2031; it is estimated to register a CAGR of 14.6% from 2023 to 2031.

Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics Boosts Asia Pacific Botulinum Toxin Market

Cosmetic surgery and injectable botulinum toxin are among the most popular noninvasive rejuvenation procedures. According to the ISAPS, in 2020, the botulinum toxin treatment was the leading noninvasive cosmetic procedure performed worldwide. Moreover, the use of botulinum toxin type A-based (BoNTA) cosmetic facial treatments are performed to improve the aesthetics of the upper and lower face. In the last decade, a facial rejuvenation procedure has gained significant popularity over different types of traditional surgeries. According to the ISAPS, ~7.3 million botulinum toxin procedures were performed globally in 2020. Thus, the surge in the adoption of botulinum toxin in facial aesthetic procedures for both men and women from all age groups is driving the botulinum toxin market growth.

Asia Pacific Botulinum Toxin Market Overview

The Asia Pacific botulinum toxin market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. The number of people suffering from headache or migraine has been rising every year, and botulinum toxin has been proven effective in reducing the frequency and severity of headaches in patients with chronic migraine. Moreover, the rising awareness of cosmetic procedures such as skin rejuvenation to improve aesthetic appeal and an increase in healthcare expenditure help to boost the growth of the botulinum toxin market in the region. The aesthetic industry in Japan has witnessed massive growth in the past. The industry is well-developed and has access to a wide range of aesthetic products. The industry is highly regulated, and hence, only licensed medical doctors perform aesthetic procedures. The market in the country is mainly driven by the increasing number of consumers willing to invest in altering and maintaining their looks. According to the ISAPS, in 2021, 458,749 botulinum toxin procedures were performed across the country. The country ranks 3rd among all the countries performing nonsurgical aesthetic procedures in the world, with share of 6.3% of the total procedures performed in the world.

Various international companies have obtained approvals for their products that treat muscle spasticity. Thus, Japanese firms have taken strategic initiatives to secure their positions in the market. In June 2021, Teijin Pharma Limited and Merz Therapeutics, a business of the Merz Group, together announced that Teijin Pharma had been granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA). To treat lower limb spasticity, Xeomin would be used in the form of intramuscular injection in 50, 100, or 200 units. This strategic move has benefited both companies for the successful launch of Xeomin to treat spasticity indication in Japan. Thus, such instances are expected to encourage more players to develop botulinum toxin for different medical conditions to enter the Japanese market.

Asia Pacific Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Botulinum Toxin Market Segmentation

The Asia Pacific botulinum toxin market is categorized into product, application, end user, and country.

Based on product, the Asia Pacific botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held a larger share of Asia Pacific botulinum toxin market share in 2023.

In terms of application, the Asia Pacific botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held a larger share of Asia Pacific botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.

By end user, the Asia Pacific botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of Asia Pacific botulinum toxin market in 2023.

Based on country, the Asia Pacific botulinum toxin market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Japan dominated the Asia Pacific botulinum toxin market share in 2023.

Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd are some of the leading companies operating in the Asia Pacific botulinum toxin market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Botulinum Toxin Market – Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
4.2 Market Restraints
4.2.1 Side Effects of Botulinum Toxin
4.3 Market Opportunities
4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
4.4 Future Trends
4.4.1 Expanding Therapeutic Applications
4.5 Impact of Drivers and Restraints:
5. Botulinum Toxin Market – Asia Pacific Analysis
5.1 Overview
5.2 Botulinum Toxin Market Revenue (US$ Million), 2021–2031
6. Asia Pacific Botulinum Toxin Market Analysis – by Product
6.1 Overview
6.2 Botulinum Toxin A
6.2.1 Overview
6.2.2 Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
6.3 Botulinum Toxin B
6.3.1 Overview
6.3.2 Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7. Asia Pacific Botulinum Toxin Market Analysis – by Application
7.1 Overview
7.2 Medical
7.2.1 Overview
7.2.2 Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.2.2.1 Asia Pacific Botulinum Toxin Market Breakdown, by Medical
7.3 Aesthetic
7.3.1 Overview
7.3.2 Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.3.2.1 Asia Pacific Botulinum Toxin Market Breakdown, by Aesthetic
8. Asia Pacific Botulinum Toxin Market Analysis – by End User
8.1 Overview
8.2 Specialty and Dermatology Clinics
8.2.1 Overview
8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Hospitals and Clinics
8.3.1 Overview
8.3.2 Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9. Asia Pacific Botulinum Toxin Market – Country Analysis
9.1 Asia Pacific: Botulinum Toxin Market
9.1.1 Asia Pacific: Botulinum Toxin Market – Revenue and Forecast Analysis – by Country
9.1.1.1 Japan
9.1.1.1.1 Overview
9.1.1.1.2 Japan: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.1.3 Japan: Botulinum Toxin Market Breakdown, by Product
9.1.1.1.4 Japan: Botulinum Toxin Market Breakdown, by Application
9.1.1.1.4.1 Japan: Botulinum Toxin Market Breakdown, by Medical
9.1.1.1.4.2 Japan: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.1.5 Japan: Botulinum Toxin Market Breakdown, by End User
9.1.1.2 China
9.1.1.2.1 Overview
9.1.1.2.2 China: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.2.3 China: Botulinum Toxin Market Breakdown, by Product
9.1.1.2.4 China: Botulinum Toxin Market Breakdown, by Application
9.1.1.2.4.1 China: Botulinum Toxin Market Breakdown, by Medical
9.1.1.2.4.2 China: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.2.5 China: Botulinum Toxin Market Breakdown, by End User
9.1.1.3 India: Botulinum Toxin Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 India: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.3.3 India: Botulinum Toxin Market Breakdown, by Product
9.1.1.3.4 India: Botulinum Toxin Market Breakdown, by Application
9.1.1.3.4.1 India: Botulinum Toxin Market Breakdown, by Medical
9.1.1.3.4.2 India: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.3.5 India: Botulinum Toxin Market Breakdown, by End User
9.1.1.4 South Korea
9.1.1.4.1 Overview
9.1.1.4.2 South Korea: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.4.3 South Korea: Botulinum Toxin Market Breakdown, by Product
9.1.1.4.4 South Korea: Botulinum Toxin Market Breakdown, by Application
9.1.1.4.4.1 South Korea: Botulinum Toxin Market Breakdown, by Medical
9.1.1.4.4.2 South Korea: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.4.5 South Korea: Botulinum Toxin Market Breakdown, by End User
9.1.1.5 Australia
9.1.1.5.1 Overview
9.1.1.5.2 Australia: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.5.3 Australia: Botulinum Toxin Market Breakdown, by Product
9.1.1.5.4 Australia: Botulinum Toxin Market Breakdown, by Application
9.1.1.5.4.1 Australia: Botulinum Toxin Market Breakdown, by Medical
9.1.1.5.4.2 Australia: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.5.5 Australia: Botulinum Toxin Market Breakdown, by End User
9.1.1.6 Rest of Asia Pacific
9.1.1.6.1 Overview
9.1.1.6.2 Rest of Asia Pacific: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.6.3 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Product
9.1.1.6.4 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Application
9.1.1.6.4.1 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Medical
9.1.1.6.4.2 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.6.5 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by End User
10. Company Profiles
10.1 Merz Pharma GmbH & Co KGaA
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 AbbVie Inc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Ipsen SA
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Evolus Inc
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Medytox Inc
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Galderma SA
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Hugel Inc
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Lanzhou Institute of Biological Products Co Ltd
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms